Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance

Overall survival (OS) has emerged as the definitive regulatory “be-all, end-all” for the demonstration of benefit in cancer clinical trials. The reason and the rationale for why this is so are easily appreciated: literally a “test of time,” OS is a seemingly unambiguous, agenda-free end point, indep...

Descripción completa

Detalles Bibliográficos
Autores principales: Oronsky, Bryan, Carter, Corey A., Reid, Tony R., Scicinski, Jan, Oronsky, Arnold, Lybeck, Michelle, Caroen, Scott, Stirn, Meaghan, Oronsky, Neil, Langecker, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611069/
https://www.ncbi.nlm.nih.gov/pubmed/26476079
http://dx.doi.org/10.1016/j.neo.2015.09.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611069/
https://www.ncbi.nlm.nih.gov/pubmed/26476079
http://dx.doi.org/10.1016/j.neo.2015.09.001

Ejemplares similares